Disease on EC 2.6.1.13 - ornithine aminotransferase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acute Kidney Injury
Inhibition of PARP overactivation protects acute kidney injury of septic shock.
Acute Lung Injury
Role of PARP on iNOS pathway during endotoxin-induced acute lung injury.
Adenocarcinoma
Evaluation of apoptosis induction using PARP cleavage on gastric adenocarcinoma and fibroblast cell lines by different strains of Helicobacter pylori.
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
Adenocarcinoma of Lung
The Joint Effect of hOGG1, APE1, and ADPRT Polymorphisms and Cooking Oil Fumes on the Risk of Lung Adenocarcinoma in Chinese Non-Smoking Females.
Alzheimer Disease
Activation of PARP by oxidative stress induced by ?-amyloid: implications for Alzheimer's disease.
arginase deficiency
Biomarkers identified in inborn errors for lysine, arginine, and ornithine.
Asthma
PARP inhibition treatment in a nonconventional experimental mouse model of chronic asthma.
PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
Atherosclerosis
PARP inhibition in atherosclerosis and its effects on dendritic cells, T cells and auto-antibody levels.
Blindness
A 15-bp deletion in exon 5 of the ornithine aminotransferase (OAT) locus associated with gyrate atrophy.
Crystal structure of human recombinant ornithine aminotransferase.
Expression defect of ornithine aminotransferase gene in gyrate atrophy.
Gyrate atrophy of the choroid and retina with hyperornithinemia: characterization of mutant liver L-ornithine:2-oxoacid aminotransferase kinetics.
Oligomeric State and Thermal Stability of Apo- and Holo- Human Ornithine ?-Aminotransferase.
Point mutation affecting processing of the ornithine aminotransferase precursor protein in gyrate atrophy.
Retrovirus-mediated gene transfer of ornithine-delta-aminotransferase into keratinocytes from gyrate atrophy patients.
Brain Diseases
Effects of inhibition of ornithine aminotransferase on thioacetamide-induced hepatogenic encephalopathy.
PARP inhibition delays progression of mitochondrial encephalopathy in mice.
Brain Injuries
At the scene of ischemic brain injury: is PARP a perp?
PARP inhibition attenuates early brain injury through NF-?B/MMP-9 pathway in a rat model of subarachnoid hemorrhage.
Brain Injuries, Traumatic
Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor.
PARP inhibition improves the effectiveness of neural stem cell transplantation in experimental brain trauma.
Brain Ischemia
Differential PARP Cleavage: An Indication of Heterogeneous Forms of Cell Death and Involvement of Multiple Proteases in the Infarct of Focal Cerebral Ischemia in Rat.
Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia.
Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation.
Brain Neoplasms
Targeted Therapy for Brain Tumours: Role of PARP Inhibitors.
Whole-body hyperthermia and ADPRT inhibition in experimental treatment of brain tumors.
Breast Neoplasms
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
Advances in PARP inhibitors for the treatment of breast cancer.
Advances in the use of PARP inhibitor therapy for breast cancer.
Androgen receptor inhibitor enhances the anti-tumor effect of PARP inhibitor in breast cancer cells by modulating DNA damage response.
ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
BiPar Sciences presents interim phase 2 results for PARP inhibitor BSI-201 at San Antonio Breast Cancer Symposium.
BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699).
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.
Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for a mouse model of BRCA1-related breast cancer.
Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP.
Correction: HP1? is a biomarker for breast cancer prognosis and PARP inhibitor therapy.
Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer.
Emerging PARP inhibitors for treating breast cancer.
Emerging therapeutic modalities of PARP inhibitors in breast cancer.
Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells.
Erratum to "Doubling Down on the PI3K-AKTmTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness" [Neoplasia 16 (2014) 43-72].
Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery.
EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic strategy.
First PARP Inhibitor Ok'd for Breast Cancer.
Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment.
Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer.
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
HP1? Is a Biomarker for Breast Cancer Prognosis and PARP Inhibitor Therapy.
In vitro cytotoxic effect of PARP inhibitor alone and in combination with nab?paclitaxel on triple?negative and luminal A breast cancer cells.
Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.
Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review.
Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
LSD1 Overexpression Is Associated with Poor Prognosis in Basal-Like Breast Cancer, and Sensitivity to PARP Inhibition.
More breast cancer patients could benefit from PARP inhibitors.
Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment.
PARP inhibition in breast cancer.
PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis.
PARP inhibitor and platinum agent in triple negative breast cancer: utilizing innovative trial design to bring together something "new" and something "old".
PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells.
PARP inhibitor treatment in ovarian and breast cancer.
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
PARP inhibitors and their evolving role in breast cancer.
PARP Inhibitors for the Treatment and Prevention of Breast Cancer.
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.
PARP Inhibitors in Breast Cancer.
PARP inhibitors in breast cancer: BRCA and beyond.
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
PARP Inhibitors in Breast Cancer: Why, How, and When?
PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
PARP inhibitors in the management of breast cancer: current data and future prospects.
PARP inhibitors stumble in breast cancer.
PARP inhibitors--current status and the walk towards early breast cancer.
PARP regulates TGF-beta receptor type II expression in estrogen receptor-positive breast cancer cell lines.
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition.
Polymorphisms of ADPRT Val762Ala and XRCC1 Arg399Glu and risk of breast cancer in Chinese women: a case control analysis.
Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer.
RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells.
Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
Resurrection of PARP Inhibitors in Breast Cancer.
Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage.
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells.
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis.
Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers.
Synergy of theophylline reduces necrotic effect of berberine, induces cell cycle arrest and PARP, HMGB1, Bcl-2 family mediated apoptosis in MDA-MB-231 breast cancer cells.
Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
TGF? induces "BRCAness" and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes.
The CDK1 inhibitor RO3306 improves the response of BRCA-pro?cient breast cancer cells to PARP inhibition.
The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Therapeutic potential of PARP inhibitors for metastatic breast cancer.
Update on PARP Inhibitors in Breast Cancer.
XRCC1 and ADPRT polymorphisms associated with survival in breast cancer cases treated with chemotherapy.
Carcinogenesis
Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis.
Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment.
[Expression and Bioinformatic Analysis of Ornithine Aminotransferase ?in Non-small Cell Lung Cancer].
Carcinoid Tumor
The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.
Carcinoma
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma.
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck.
Identification of a yeast artificial chromosome that spans the human papillary renal cell carcinoma-associated t(X;1) breakpoint in Xp11.2.
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.
PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives.
Proteome of Metastatic Canine Mammary Carcinomas: Similarities to and Differences from Human Breast Cancer (†).
Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages.
Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo.
The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
The Role of PARP Inhibitors in the Treatment of Ovarian Carcinomas.
[Inhibitory effect of 5-aminoisoquinolinone on PARP activity in colon carcinoma cell line HT-29]
Carcinoma, Hepatocellular
EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma.
Establishment of a clonal strain of hepatoma cells derived from Morris hepatoma 8999.
Expression mechanism of abnormality of ornithine aminotransferase level in Morris hepatomas.
Imbalance in ornithine metabolism in hepatomas of different growth rates as expressed in behavior of L-ornithine:2-oxoacid aminotransferase (ornithine transaminase, EC 2.6.1.13).
No associations of polymorphisms in ADPRT with hepatitis B virus clearance and hepatocellular carcinoma occurrence in a Korean population.
PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models.
Studies on the turnover rates of ornithine aminotransferase in Morris hepatoma 44 and host liver.
Suppression of Hepatocellular Carcinoma by Inhibition of Overexpressed Ornithine Aminotransferase.
Carcinoma, Non-Small-Cell Lung
APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.
Ornithine aminotransferase promoted the proliferation and metastasis of non-small cell lung cancer via upregulation of miR-21.
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
Pelargonium quercetorum Agnew induces apoptosis without PARP or cytokeratin 18 cleavage in non-small cell lung cancer cell lines.
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer: Methodological Issues.
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer.
Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.
Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
Carcinoma, Ovarian Epithelial
A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance.
Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry.
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide.
Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.
Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.
PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check.
PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.
PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.
PARP inhibitors in epithelial ovarian cancer.
PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
The circuitous path of PARP inhibitor development in epithelial ovarian cancer.
The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer.
The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.
Carcinoma, Renal Cell
Identification of a yeast artificial chromosome that spans the human papillary renal cell carcinoma-associated t(X;1) breakpoint in Xp11.2.
Carcinoma, Squamous Cell
Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP.
Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck.
Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo.
Carcinoma, Transitional Cell
Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages.
Cardiotoxicity
The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.
Cardiovascular Diseases
Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
Cataract
Associations of PARP-1 variant rs1136410 with PARP activities, oxidative DNA damage, and the risk of age-related cataract in a Chinese Han population: A two-stage case-control analysis.
Cholangiocarcinoma
PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.
Choroideremia
Regional expression of disease-related genes in human and monkey retina.
Colonic Neoplasms
Analysis of differentially expressed genes in human hepatocellular carcinoma using suppression subtractive hybridization.
Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.
Downregulation of NIT2 inhibits colon cancer cell proliferation and induces cell cycle arrest through the caspase-3 and PARP pathways.
Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan.
Terpenes from essential oils and hydrolate of Teucrium alopecurus triggered apoptotic events dependent on caspases activation and PARP cleavage in human colon cancer cells through decreased protein expressions.
The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.
Colorectal Neoplasms
A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.
ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib.
In Vitro and In Vivo Enhancement of Chemoradiation Using the Oral PARP Inhibitor ABT-888 in Colorectal Cancer Cells.
Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status.
Craniocerebral Trauma
A novel PARP inhibitor L-2286 in a rat model of impact acceleration head injury: An immunohistochemical and behavioral study.
Cystinosis
Sedoheptulokinase deficiency due to a 57-kb deletion in cystinosis patients causes urinary accumulation of sedoheptulose: elucidation of the CARKL gene.
Cystitis
Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation.
Protein nitration, PARP activation and NAD+ depletion may play a critical role in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis in the rat.
Dehydration
Effect of drought on polyamine metabolism, yield, protein content and in vitro protein digestibility in tepary (Phaseolus acutifolius) and common (Phaseolus vulgaris) bean seeds
Water deficit-induced oxidative stress affects artemisinin content and expression of proline metabolic genes in Artemisia annua L.
Dermatitis, Phototoxic
The PARP inhibitor PJ-34 sensitizes cells to UVA-induced phototoxicity by a PARP independent mechanism.
Diabetes Mellitus, Experimental
Tempol reduces podocyte apoptosis via PARP signaling pathway in experimental diabetes mellitus.
Diabetes Mellitus, Type 1
Contribution of type 1 diabetes to rat liver dysfunction and cellular damage via activation of NOS, PARP, IkappaBalpha/NF-kappaB, MAPKs, and mitochondria-dependent pathways: Prophylactic role of arjunolic acid.
Diabetes Mellitus, Type 2
PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.
The relationship between obstructive sleep apnea and intra-epidermal nerve fiber density, PARP activation and foot ulceration in patients with type 2 diabetes.
Diabetic Cardiomyopathies
PARP mediates structural alterations in diabetic cardiomyopathy.
Diabetic Nephropathies
Gallotannin ameliorates the development of streptozotocin-induced diabetic nephropathy by preventing the activation of PARP.
Diabetic Neuropathies
New Therapeutic and Biomarker Discovery for Peripheral Diabetic Neuropathy: PARP Inhibitor, Nitrotyrosine, and Tumor Necrosis Factor-{alpha}
PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy.
Diabetic Retinopathy
Role of nitric oxide, superoxide, peroxynitrite and PARP in diabetic retinopathy.
Endometrial Neoplasms
Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis.
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Endotoxemia
Adaptative response of nitrogen metabolism in early endotoxemia: role of ornithine aminotransferase.
Systemic and hepatosplanchnic hemodynamic and metabolic effects of the PARP inhibitor PJ34 during hyperdynamic porcine endotoxemia.
Ependymoma
PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.
Eye Diseases
A single-base change at a splice acceptor site in the ornithine aminotransferase gene causes abnormal RNA splicing in gyrate atrophy.
Molecular basis of ornithine aminotransferase deficiency in B-6-responsive and -nonresponsive forms of gyrate atrophy.
Splicing defect at the ornithine aminotransferase (OAT) locus in gyrate atrophy.
Fanconi Anemia
Acquisition of relative interstrand crosslinker resistance and PARP inhibitor sensitivity in Fanconi anemia head and neck cancers.
The Fanconi anemia cell line HSC536N is not sensitive to interferon-gamma and does not cleave PARP in response to FAS-mediated cell killing.
Fatty Liver
PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Steatohepatitis: PARP inhibition protective against alcoholic steatohepatitis and NASH.
Fatty Liver, Alcoholic
Steatohepatitis: PARP inhibition protective against alcoholic steatohepatitis and NASH.
Genetic Diseases, Inborn
Crystal structure of human recombinant ornithine aminotransferase.
Glioblastoma
Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.
Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.
Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent.
Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition.
Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors.
PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity.
Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation.
Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.
Glioma
Comparative status of activated ERK1/2 and PARP cleavage in human gliomas.
Differential PARP cleavage: an indication for existence of multiple forms of cell death in human gliomas.
H2O2-induced cell death in human glioma cells: role of lipid peroxidation and PARP activation.
Oxidative stress and PARP activation mediate the NADH-induced decrease in glioma cell survival.
PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.
PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma.
TCH1036, a indeno[1,2-c]quinoline derivative, potentially inhibited the growth of human brain malignant glioma (GBM) 8401 cells via suppression of the expression of Suv39h1 and PARP.
Gyrate Atrophy
A 15-bp deletion in exon 5 of the ornithine aminotransferase (OAT) locus associated with gyrate atrophy.
A deletion in the ornithine aminotransferase gene in gyrate atrophy.
A mouse model of gyrate atrophy of the choroid and retina. Early retinal pigment epithelium damage and progressive retinal degeneration.
A new sensitive and convenient assay of ornithine aminotransferase.
A single amino acid substitution within the mature sequence of ornithine aminotransferase obstructs mitochondrial entry of the precursor.
A single-base change at a splice acceptor site in the ornithine aminotransferase gene causes abnormal RNA splicing in gyrate atrophy.
A specific enzyme defect in gyrate atrophy.
An initiator codon mutation in ornithine-delta-aminotransferase causing gyrate atrophy of the choroid and retina.
Analysis of the human ornithine aminotransferase gene family.
At least two mutant alleles of ornithine delta-aminotransferase cause gyrate atrophy of the choroid and retina in Finns.
Bevacizumab for the treatment of intraretinal cystic spaces in a patient with gyrate atrophy of the choroid and retina.
Carbonic anhydrase inhibitor with topical NSAID therapy to manage cystoid macular edema in a case of gyrate atrophy.
Central nervous system involvement in gyrate atrophy of the choroid and retina with hyperornithinaemia.
Chromosomal localization of human ornithine aminotransferase gene sequences to 10q26 and Xp11.2.
Clinical trial of vitamin B6 for gyrate atrophy of the choroid and retina.
Comparison of ornithine metabolism in hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome, lysinuric protein intolerance and gyrate atrophy fibroblasts.
Correction of ornithine accumulation prevents retinal degeneration in a mouse model of gyrate atrophy of the choroid and retina.
Correction of ornithine-delta-aminotransferase deficiency in a Chinese hamster ovary cell line mediated by retrovirus gene transfer.
Crystal structure of human recombinant ornithine aminotransferase.
Cystoid macular edema secondary to gyrate atrophy in a child treated with sub-tenon injection of triamcinolone acetonide.
Cytotoxic effect of spermine on retinal pigment epithelial cells.
Defective ornithine metabolism in cultured skin fibroblasts from patients with the syndrome of hyperornithinemia, hyperammonemia and homocitrullinuria.
Detection of point mutations associated with genetic diseases by an exon scanning technique.
Dietary compliance in ornithine aminotransferase deficiency.
Expression and processing of human ornithine-delta-aminotransferase in Saccharomyces cerevisiae.
Expression defect of ornithine aminotransferase gene in gyrate atrophy.
Expression of human ornithine aminotransferase (OAT) in OAT-deficient Chinese hamster ovary cells and fibroblasts of gyrate atrophy patient.
Functional analysis of missense mutations of OAT, causing gyrate atrophy of choroid and retina.
Gene transfer and expression of human ornithine aminotransferase.
Genotype-phenotype correlation of a pyridoxine-responsive form of gyrate atrophy.
Gyrate atrophy of the choroid and retina in a 5-year-old girl.
Gyrate atrophy of the choroid and retina with hyperornithinemia. Deficient formation of guanidinoacetic acid from arginine.
Gyrate atrophy of the choroid and retina with hyperornithinemia: characterization of mutant liver L-ornithine:2-oxoacid aminotransferase kinetics.
Gyrate atrophy of the choroid and retina.
Gyrate atrophy of the choroid and retina. A five-year follow-up of creatine supplementation.
Gyrate atrophy of the choroid and retina. Biochemical considerations and experience with an arginine-restricted diet.
Gyrate atrophy of the choroid and retina: assignment of the ornithine aminotransferase structural gene to human chromosome 10 and mouse chromosome 7.
Gyrate atrophy of the choroid and retina: characterization of mutant ornithine aminotransferase and mechanism of response to vitamin B6.
Gyrate atrophy of the choroid and retina: decreased ornithine aminotransferase concentration in cultured skin fibroblasts from patients.
Gyrate atrophy of the choroid and retina: deficiency of ornithine aminotransferase in transformed lymphocytes.
Gyrate atrophy of the choroid and retina: lymphocyte ornithine-delta-aminotransferase activity in different mutations and carriers.
Gyrate atrophy of the retina and choroid is an inborn error of metabolism of ornithine aminotransferase.
Gyrate atrophy of the retina and choroid. Two methods for prenatal diagnosis.
Heterogeneity and uniqueness of ornithine aminotransferase mutations found in Japanese gyrate atrophy patients.
Heterogeneity in ornithine cytotoxicity of bovine retinal pigment epithelial cells in primary culture.
Immunocytochemical localization of ornithine aminotransferase in human ocular tissues.
Immunocytochemical localization of ornithine aminotransferase in rat ocular tissues.
Immunohistochemical localization of ornithine aminotransferase in normal rat tissues by Fab'-horseradish peroxidase conjugates.
Induction of arginase II mRNA by nitric oxide using in vitro model of gyrate atrophy of choroid and retina.
Inheritance of ornithine aminotransferase gene, mRNA, and enzyme defect in a family with gyrate atrophy of the choroid and retina.
Inhibition of arginine-glycine amidinotransferase by ornithine. A possible mechanism for the muscular and chorioretinal atrophies in gyrate atrophy of the choroid and retina with hyperornithinemia.
Investigation of gyrate atrophy using a cDNA clone for human ornithine aminotransferase.
Mapping of ornithine aminotransferase gene sequences to mouse chromosomes 7, X, and 3.
Metabolic follow-up of a Croatian patient with gyrate atrophy and a new mutation in the OAT gene: a case report.
Mice lacking ornithine-delta-aminotransferase have paradoxical neonatal hypoornithinaemia and retinal degeneration.
Molecular basis of ornithine aminotransferase defect in gyrate atrophy.
Molecular basis of ornithine aminotransferase deficiency in B-6-responsive and -nonresponsive forms of gyrate atrophy.
Molecular genetics of ornithine aminotransferase defect in gyrate atrophy.
Molecular pathology of gyrate atrophy of the choroid and retina due to ornithine aminotransferase deficiency.
Nonsense-codon mutations of the ornithine aminotransferase gene with decreased levels of mutant mRNA in gyrate atrophy.
Oligomeric State and Thermal Stability of Apo- and Holo- Human Ornithine ?-Aminotransferase.
Ophthalmologic heterogeneity in subjects with gyrate atrophy of choroid and retina harboring the L402P mutation of ornithine aminotransferase.
Ornithine Aminotransferase Deficiency in Differential Diagnosis of Neonatal Hyperammonemia: A Case with a Novel OAT Gene Mutation.
Ornithine aminotransferase deficiency: diagnostic difficulties in neonatal presentation.
Ornithine aminotransferase distribution in ocular tissues and retinas of cat and mouse.
Ornithine delta-aminotransferase mutations in gyrate atrophy. Allelic heterogeneity and functional consequences.
Ornithine transport via cationic amino acid transporter-1 is involved in ornithine cytotoxicity in retinal pigment epithelial cells.
Ornithine-delta-aminotransferase expression and ornithine metabolism in cultured epidermal keratinocytes: toward metabolic sink therapy for gyrate atrophy.
Pathology of iridectomy specimens in gyrate atrophy of the retina and choroid.
Point mutation affecting processing of the ornithine aminotransferase precursor protein in gyrate atrophy.
Possible role of polyamines in gyrate atrophy.
Prevention of ornithine cytotoxicity by nonpolar side chain amino acids in retinal pigment epithelial cells.
Prevention of ornithine cytotoxicity by proline in human retinal pigment epithelial cells.
Pyridoxine-responsive gyrate atrophy of the choroid and retina: clinical and biochemical correlates of the mutation A226V.
Rapid and efficient molecular analysis of gyrate atrophy using denaturing gradient gel electrophoresis.
Regulation of proline biosynthesis: the inhibition of pyrroline-5-carboxylate synthase activity by ornithine.
Retrovirus-mediated gene transfer of ornithine-delta-aminotransferase into keratinocytes from gyrate atrophy patients.
Secondary creatine deficiency in ornithine delta-aminotransferase deficiency.
Splicing defect at the ornithine aminotransferase (OAT) locus in gyrate atrophy.
The ornithine aminotransferase (OAT) locus: analysis of RFLPs in gyrate atrophy.
The ornithine aminotransferase gene in gyrate atrophy of the retina: analysis of expression and gross structure of this gene in cultured fibroblasts.
The skipping of constitutive exons in vivo induced by nonsense mutations.
Three novel mutations of the ornithine aminotransferase (OAT) gene in gyrate atrophy.
Vitamin B6-responsive ornithine aminotransferase deficiency with a novel mutation G237D.
[Fuchs' gyrate atrophy and ornithine aminotransferase deficiency]
[Gyrate atrophy of late disclosure]
[Hyperornithinemia and gyrate atrophy: ornithine aminotransferase gene error causing a Finnish disease]
[Molecular cloning of the genes in genetic chorioretinal diseases--positional cloning and the candidate gene approach]
[Vitamin B6 dependency syndrome]
Heart Failure
Additional use of immunostaining for active caspase 3 and cleaved actin and PARP fragments to detect apoptosis in patients with chronic heart failure.
PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.
PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.
Hepatitis B
No associations of polymorphisms in ADPRT with hepatitis B virus clearance and hepatocellular carcinoma occurrence in a Korean population.
Hepatitis C
Hepatitis C virus induces oxidative stress and DNA damage by regulating DNAPKCs, ATM, ATR and PARP mediated signaling and guards cell from cancerous condition by upregulating RB, P53 and downregulating VEGF.
Hepatomegaly
Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas.
Homocystinuria
[Phaenotypic aspects of hereditary aminoacidopathies (author's transl)]
Huntington Disease
Ornithine aminotransferase in Huntington's disease.
Hyperargininemia
Biomarkers identified in inborn errors for lysine, arginine, and ornithine.
Hyperglycemia
Parp inhibition prevents ten eleven translocase enzyme activation and hyperglycemia induced DNA demethylation.
Hypersensitivity
A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition.
Base excision repair defects invoke hypersensitivity to PARP inhibition.
Hypersensitivity of BRCA2 deficient cells to rosemary extract explained by weak PARP inhibitory activity.
Hypertension, Pulmonary
MicroRNAs and PARP: co-conspirators with ROS in pulmonary hypertension. Focus on "miR-223 reverses experimental pulmonary arterial hypertension".
Hyperthyroidism
Role of thyroxine in the postnatal development of rat hepatic tryptophan oxygenase and ornithine aminotransferase.
Infection
Helicobacter pylori in a Korean Isolate Expressed Proteins Differentially in Human Gastric Epithelial Cells.
Interactions of ibuprofen with influenza infection and hyperammonemia in an animal model of Reye's syndrome.
Influenza, Human
Interactions of ibuprofen with influenza infection and hyperammonemia in an animal model of Reye's syndrome.
Leukemia
A Phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms and chronic myelomonocytic leukemia.
Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells.
Combinatorial Effects of PARP Inhibitor PJ34 and Histone Deacetylase Inhibitor Vorinostat on Leukemia Cell Lines.
Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia.
PARP inhibitor re?sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis.
PARP Inhibitors Suppress AML1-ETO- and PML-RAR?-Positive Leukemia.
Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.
The combination of the PARP inhibitor rucaparib and 5FU is an effective strategy for treating acute leukemias.
Leukemia, Myeloid, Acute
A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia.
BRCA1, PARP1 and ?H2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
Leukemia, Myelomonocytic, Chronic
A Phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms and chronic myelomonocytic leukemia.
Leukemia-Lymphoma, Adult T-Cell
Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells.
Liver Diseases
Contribution of type 1 diabetes to rat liver dysfunction and cellular damage via activation of NOS, PARP, IkappaBalpha/NF-kappaB, MAPKs, and mitochondria-dependent pathways: Prophylactic role of arjunolic acid.
Liver Neoplasms
Combination PARP and HDAC inhibition as a therapeutic strategy targeting liver cancer stem cells?
Liver Neoplasms, Experimental
Studies on the turnover rates of ornithine aminotransferase in Morris hepatoma 44 and host liver.
Lung Neoplasms
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Fucoidan upregulates TLR4/CHOP-mediated caspase-3 and PARP activation to enhance cisplatin-induced cytotoxicity in human lung cancer cells.
Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer.
Nanopharmaceutical Approach for Enhanced Anti-cancer Activity of Betulinic Acid in Lung-cancer Treatment via Activation of PARP: Interaction with DNA as a Target: -Anti-cancer Potential of Nano-betulinic Acid in Lung Cancer.
Ornithine aminotransferase promoted the proliferation and metastasis of non-small cell lung cancer via upregulation of miR-21.
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
PARP inhibitor activates the intrinsic pathway of apoptosis in primary lung cancer cells.
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
PARP inhibitors in lung cancer.
PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.
Pelargonium quercetorum Agnew induces apoptosis without PARP or cytokeratin 18 cleavage in non-small cell lung cancer cell lines.
Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer.
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
Quantitative proteomic analysis of mitochondrial proteins differentially expressed between small cell lung cancer cells and normal human bronchial epithelial cells.
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer: Methodological Issues.
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer.
Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.
Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
Target engagement imaging of PARP inhibitors in small-cell lung cancer.
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.
Lupus Erythematosus, Systemic
PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus.
Lymphoma
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.
Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition.
Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells.
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
Ligation of CD40 potentiates Fas-mediated activation of the cysteine protease CPP32, cleavage of its death substrate PARP, and apoptosis in Ramos-Burkitt lymphoma B cells.
Ligation of CD40 rescues Ramos-Burkitt lymphoma B cells from calcium ionophore- and antigen receptor-triggered apoptosis by inhibiting activation of the cysteine protease CPP32/Yama and cleavage of its substrate PARP.
PARP activation promotes nuclear AID accumulation in lymphoma cells.
Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas.
The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
Tissue enzyme changes in parabiotic rats with subcutaneous lymphoma or fibrosarcoma.
Lymphoma, B-Cell
The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma.
Lymphoma, Mantle-Cell
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
Medulloblastoma
Medulloblastoma in mice lacking p53 and PARP: all roads lead to Gli.
PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.
Melanoma
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma.
Inhibition of PARP activity by PJ-34 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line.
Meningococcal Infections
Polymorphisms in PARP, IL1B, IL4, IL10, C1INH, DEFB1 and DEFA4 in meningococcal disease in three populations.
Metabolic Diseases
Cystoid macular edema secondary to gyrate atrophy in a child treated with sub-tenon injection of triamcinolone acetonide.
Multiple Myeloma
A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
Muscular Dystrophies
Serine protease in mice with hereditary muscular dystrophy.
Myocardial Infarction
Protective effect of diethylcarbamazine inhibits NF-?B activation in isoproterenol-induced acute myocardial infarction rat model through the PARP pathway.
Myocardial Ischemia
Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size.
Nasopharyngeal Carcinoma
Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors.
Neoplasm Metastasis
Ornithine aminotransferase promoted the proliferation and metastasis of non-small cell lung cancer via upregulation of miR-21.
Quantitative proteomic analysis of mitochondrial proteins differentially expressed between small cell lung cancer cells and normal human bronchial epithelial cells.
SOX2 inhibits cell proliferation and metastasis, promotes apoptotic by downregulating CCND1 and PARP in gastric cancer.
Neoplasms
6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.
A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models.
A Phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms and chronic myelomonocytic leukemia.
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells.
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
Accelerated gene transfer through a polysorbitol-based transporter mechanism.
Acquisition of relative interstrand crosslinker resistance and PARP inhibitor sensitivity in Fanconi anemia head and neck cancers.
Advances in using PARP inhibitors to treat cancer.
An update on PARP inhibitors for the treatment of cancer.
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition.
Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.
Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Cancer during pregnancy alters the activity of rat placenta and enhances the expression of cleaved PARP, cytochrome-c and caspase 3.
Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.
Chemopotentiation by PARP inhibitors in cancer therapy.
Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors.
cis-[RuCl(BzCN) (bipy) (dppe)]PF6 induces anti-angiogenesis and apoptosis by a mechanism of caspase-dependent involving DNA damage, PARP activation, and Tp53 induction in Ehrlich tumor cells.
Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
Correction: Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program.
Cyclic hypoxia does not alter RAD51 expression or PARP inhibitor cell kill in tumor cells.
Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.
Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells.
Development of PARP inhibitors in gynecological malignancies.
Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer.
Discussion of PARP inhibitors in cancer therapy.
Drug Driven Synthetic Lethality: bypassing tumor cell genetics with a combination of Dbait and PARP inhibitors.
Editorial: Inhibiting PARP as a Strategic Target in Cancer.
Effect of tumors with different growth rates on enzymes in host liver.
Efficacy of the Combination of a PARP Inhibitor and UVC on Cancer Cells as Imaged by Focus Formation by the DNA Repair-related Protein 53BP1 Linked to Green Fluorescent Protein.
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
Erratum for the Perspective: "Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action" by Y. Pommier, M. J. O'Connor, J. de Bono.
Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers.
Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.
Gynaecological cancer: PARP inhibition - moving beyond BRCA-mutated disease.
HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair.
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Hypolipidemic drug clofibrate induces hepatic dedifferentiation.
Identification of differentially expressed proteins in spontaneous thymic lymphomas from knockout mice with deletion of p53.
Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition.
In Vitro Long-Term Proliferation Assays to Study Antiproliferative Effects of PARP Inhibitors on Cancer Cells.
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo.
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a Bona Fide PARP inhibitor.
Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?
Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.
Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition.
Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.
Mapping Metabolic Events in the Cancer Cell Cycle Reveals Arginine Catabolism in the Committed SG2M Phase.
Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response.
Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2.
Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
Molecular Pathways: Targeting PARP in Cancer Treatment.
NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression.
New PARP targets for cancer therapy.
New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
New Therapeutic and Biomarker Discovery for Peripheral Diabetic Neuropathy: PARP Inhibitor, Nitrotyrosine, and Tumor Necrosis Factor-{alpha}
NF?B Down-regulation and PARP Cleavage by Novel 3-?-Butyryloxy-?-boswellic Acid Results in Cancer Cell Specific Apoptosis and in vivo Tumor Regression.
Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
Ornithine aminotransferase activity in lung & mammary tumours.
Ornithine aminotransferase promoted the proliferation and metastasis of non-small cell lung cancer via upregulation of miR-21.
Overexpression of dominant negative PARP interferes with tumor formation of HeLa cells in nude mice: evidence for increased tumor cell apoptosis in vivo.
Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.
PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.
PARP and other prospective targets for poisoning cancer cell metabolism.
PARP and PARG Inhibitors-New Therapeutic Targets in Cancer Treatment.
PARP cleavage and perturbance in mitochondrial membrane potential by 3-?-propionyloxy-?-boswellic acid results in cancer cell death and tumor regression in murine models.
PARP expression in germ cell tumours.
PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials.
PARP inhibition causes premature loss of cohesion in cancer cells.
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2.
PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?
PARP inhibitor attenuated colony formation can be restored by MAP kinase inhibitors in different irradiated cancer cell lines.
PARP inhibitor development for systemic cancer targeting.
PARP inhibitor tilts cell death from necrosis to apoptosis in cancer cells.
PARP inhibitors and cancer therapy - early results and potential applications.
PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.
PARP inhibitors blaze a trail in difficult-to-treat cancers.
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
PARP inhibitors for cancer therapy.
PARP Inhibitors for Cancer Therapy.
PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.
PARP inhibitors in cancer therapy: an update.
PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets.
PARP inhibitors in cancer therapy: promise, progress, and puzzles.
PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.
PARP inhibitors in cancer: moving beyond BRCA.
PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.
PARP inhibitors in ovarian and other cancers.
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
PARP Inhibitors: Extending Benefit Beyond BRCA Mutant Cancers.
PARP inhibitors: its role in treatment of cancer.
PARP Inhibitors: Mechanism of Action and Their Potential Role in the Prevention and Treatment of Cancer.
PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases.
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow.
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas.
Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.
Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment.
Polymorphisms of DNA repair genes: ADPRT, XRCC1, and XPD and cancer risk in genetic epidemiology.
Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.
Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.
Predictive biomarkers for cancer therapy with PARP inhibitors.
Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.
QSAR study of 2-(1-Propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide as PARP inhibitors for treatment of cancer.
Quantitative proteomic analysis of mitochondrial proteins differentially expressed between small cell lung cancer cells and normal human bronchial epithelial cells.
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells.
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.
Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.
Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation.
Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials.
Role of PARP Inhibitors in Cancer Biology and Therapy.
Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.
Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules.
Sensitizing HR-proficient cancers to PARP inhibitors.
Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers.
Successes and Challenges of PARP Inhibitors in Cancer Therapy.
Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program.
Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms.
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.
Synthetic lethality and cancer: cohesin and PARP at the replication fork.
Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-?
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
Targeted therapy for cancer using PARP inhibitors.
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models.
TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy.
The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.
The development of PARP as a successful target for cancer therapy.
The effect of lymphoma and other neoplasms on hepatic and plasma enzymes of the host rat.
The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells.
The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity.
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways.
The PARP inhibitor olaparib induces significant killing of ATM deficient lymphoid tumour cells in vitro and in vivo.
The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.
The potential role and application of PARP inhibitors in cancer treatment.
The promise of combining inhibition of PI3K and PARP as cancer therapy.
The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies.
The telomeric PARP, tankyrases, as targets for cancer therapy.
The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients.
The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy; Use as a Single Agent in Susceptible Patients; Techniques Used to Identify Susceptible Patients.
Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition.
Tumor Suppression by PARP Inhibitors Is Potentiated by c-MET Inhibition.
Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules.
[BRCA diagnostics of ovarian cancer : Molecular tumor testing since the introduction of PARP inhibitor therapy].
[Enhancement of bleomycin or hyperthermia induced tumor cell damage by ADPRT inhibitor]
[Expression and Bioinformatic Analysis of Ornithine Aminotransferase ?in Non-small Cell Lung Cancer].
[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Neoplasms, Germ Cell and Embryonal
PARP expression in germ cell tumours.
Neuralgia
PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy.
Neuroblastoma
Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition.
Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.
Neurodegenerative Diseases
Proteome response to ochratoxin A-induced apoptotic cell death in mouse hippocampal HT22 cells.
Neuroendocrine Tumors
Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor.
Nijmegen Breakage Syndrome
DNA Damage in Nijmegen Breakage Syndrome Cells Leads to PARP Hyperactivation and Increased Oxidative Stress.
Non-alcoholic Fatty Liver Disease
New Potential Biomarker Proteins for Alcoholic Liver Disease Identified by a Comparative Proteomics Approach.
ornithine aminotransferase deficiency
A new sensitive and convenient assay of ornithine aminotransferase.
Biomarkers identified in inborn errors for lysine, arginine, and ornithine.
Correction of ornithine-delta-aminotransferase deficiency in a Chinese hamster ovary cell line mediated by retrovirus gene transfer.
Dietary compliance in ornithine aminotransferase deficiency.
Gyrate atrophy of the choroid and retina in a 5-year-old girl.
Gyrate atrophy of the choroid and retina. Biochemical considerations and experience with an arginine-restricted diet.
Hyperornithinaemia and gyrate atrophy of the retina: improvement of vision during treatment with a low-arginine diet.
Molecular basis of ornithine aminotransferase deficiency in B-6-responsive and -nonresponsive forms of gyrate atrophy.
Molecular pathology of gyrate atrophy of the choroid and retina due to ornithine aminotransferase deficiency.
Ornithine Aminotransferase Deficiency in Differential Diagnosis of Neonatal Hyperammonemia: A Case with a Novel OAT Gene Mutation.
Ornithine aminotransferase deficiency: diagnostic difficulties in neonatal presentation.
Pathology of iridectomy specimens in gyrate atrophy of the retina and choroid.
Secondary creatine deficiency in ornithine delta-aminotransferase deficiency.
Sustained oral lysine supplementation in ornithine delta-aminotransferase deficiency.
Vitamin B6-responsive ornithine aminotransferase deficiency with a novel mutation G237D.
[Fuchs' gyrate atrophy and ornithine aminotransferase deficiency]
Osteosarcoma
Differentiative pathway activated by 3-aminobenzamide, an inhibitor of PARP, in human osteosarcoma MG-63 cells.
Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.
Ovarian Neoplasms
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP.
Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population.
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition.
Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Combining PI3K and PARP inhibitors for breast and ovarian cancer treatment.
Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer.
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study.
Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors.
Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.
FDA approves PARP inhibitor for ovarian cancer.
Identification of DNA Repair Pathways that Affect the Survival of Ovarian Cancer Cells Treated with a PARP Inhibitor in a Novel Drug Combination.
Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer.
Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
Making the best of PARP inhibitors in ovarian cancer.
miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
New treatment option for ovarian cancer: PARP inhibitors.
Olaparib: a promising PARP inhibitor in ovarian cancer therapy.
PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials.
PARP inhibition and synthetic lethality in ovarian cancer.
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
PARP inhibition in BRCA-mutated breast and ovarian cancers.
PARP inhibition in ovarian cancer: state of the science.
PARP Inhibition Induces Enrichment of DNA Repair-Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells.
PARP inhibition: A promising therapeutic target in ovarian cancer.
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
PARP inhibitors and quality of life in ovarian cancer.
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
PARP inhibitors for ovarian cancer.
PARP inhibitors for targeted treatment in ovarian cancer.
Parp Inhibitors for the Treatment of Ovarian Cancer.
PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.
PARP inhibitors in BRCA mutation-associated ovarian cancer.
PARP Inhibitors in Ovarian Cancer Treatment.
PARP inhibitors in ovarian cancer.
PARP Inhibitors in Ovarian Cancer.
PARP inhibitors in ovarian cancer.
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions.
PARP inhibitors in ovarian cancer: Current status and future promise.
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential.
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.
Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer.
Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.
Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.
Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use.
Targeted therapy: ARIEL3 - broad benefit of PARP inhibitors in ovarian cancer.
Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models.
The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
The current status of PARP inhibitors in ovarian cancer.
The development of PARP inhibitors in ovarian cancer: from bench to bedside.
The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.
The maze of PARP inhibitors in ovarian cancer.
The potential of PARP inhibitors in genetic breast and ovarian cancers.
The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.
The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.
Triapine Disrupts CtIP-Mediated Homologous Recombination Repair and Sensitizes Ovarian Cancer Cells to PARP and Topoisomerase Inhibitors.
Using PARP Inhibitors in Advanced Ovarian Cancer.
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
[BRCA diagnostics of ovarian cancer : Molecular tumor testing since the introduction of PARP inhibitor therapy].
Pancreatic Neoplasms
A PARP inhibitor in pancreatic cancer: Enhancement anti-tumour activity of chemoradiation therapy against pancreatic cancer?
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib.
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity.
PARP Inhibitor Drugs In The Treatment Of Breast, Ovarian, Prostate And Pancreatic Cancers: An Update of Clinical Trials.
Parkinson Disease
PARP Inhibitors and Parkinson's Disease.
Parp mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson's disease.
The expression of PARP, NF-kappa B and parvalbumin is increased in Parkinson disease.
Peripheral Nervous System Diseases
Morin Mitigates Chronic Constriction Injury (CCI)-Induced Peripheral Neuropathy by Inhibiting Oxidative Stress Induced PARP Over-Activation and Neuroinflammation.
PARP inhibition attenuates neuroinflammation and oxidative stress in chronic constriction injury induced peripheral neuropathy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia.
Good early treatment response in childhood acute lymphoblastic leukemia is associated with Bax nuclear accumulation and PARP cleavage.
Prostatic Neoplasms
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy.
Beyond hormone therapy for prostate cancer with PARP inhibitors.
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
Effects of INPP4B gene transfection combined with PARP inhibitor on castration therapy-resistant prostate cancer cell line, PC3.
Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer.
Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation.
PARP inhibition in BRCA2-mutated prostate cancer.
PARP inhibition in castration-resistant prostate cancer.
PARP Inhibition in Prostate Cancer: A Promising Approach.
PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells.
PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations.
PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
PARP inhibitors and stratified treatment of prostate cancer.
PARP inhibitors for homologous recombination-deficient prostate cancer.
PARP Inhibitors in Prostate Cancer.
Prostate cancer: Potential of PARP inhibition plus ADT in prostate cancer.
Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation.
Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case Report.
Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer.
Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function.
The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.
The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition.
Rectal Neoplasms
PARP inhibitors and chemoradiation for rectal cancer.
Renal Insufficiency
Messenger RNA for enzymes of ornithine and polyamine metabolism are selectively underexpressed in kidney of 5/6 nephrectomized rats.
Reperfusion Injury
Effects of 3-aminobenzamide on unilateral testicular ischemia-reperfusion injury: what is the role of PARP inhibition?
Retinal Degeneration
Dietary compliance in ornithine aminotransferase deficiency.
Gyrate atrophy of the retina and choroid is an inborn error of metabolism of ornithine aminotransferase.
Mice lacking ornithine-delta-aminotransferase have paradoxical neonatal hypoornithinaemia and retinal degeneration.
Pathology of iridectomy specimens in gyrate atrophy of the retina and choroid.
Retinitis Pigmentosa
Efficacy of PARP inhibition in Pde6a mutant mouse models for retinitis pigmentosa depends on the quality and composition of individual human mutations.
Retinoblastoma
Regulation of ornithine aminotransferase in retinoblastomas.
Rhabdomyosarcoma, Embryonal
PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.
Sarcoma
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.
Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors?
Sarcoma, Ewing
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma.
PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.
Poly(ADP-ribose) polymerase turnover alterations do not contribute to PARP overexpression in Ewing's sarcoma cells.
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Sarcoma, Synovial
A synovial sarcoma with a complex t(X;18;5;4) and a break in the ornithine aminotransferase (OAT)L1 cluster on Xp11.2.
Identification of a yeast artificial chromosome that spans the human papillary renal cell carcinoma-associated t(X;1) breakpoint in Xp11.2.
Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor.
Scleroderma, Systemic
PARP activity and NAD concentration in PMC from patients affected by systemic sclerosis and lupus erythematosus.
sedoheptulokinase deficiency
Characterization of mammalian sedoheptulokinase and mechanism of formation of erythritol in sedoheptulokinase deficiency.
First two unrelated cases of isolated sedoheptulokinase deficiency: A benign disorder?
Sedoheptulokinase deficiency due to a 57-kb deletion in cystinosis patients causes urinary accumulation of sedoheptulose: elucidation of the CARKL gene.
Seizures
Enhanced endogenous ornithine concentrations protect against tonic seizures and coma in acute ammonia intoxication.
Functional significance of the activities of glutaminase and ornithine-?-aminotransferase in rat brain.
Shock, Septic
Inhibition of PARP overactivation protects acute kidney injury of septic shock.
Skin Diseases
Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease.
Skin Neoplasms
Induction of apoptosis in A431 skin cancer cells by Cissus quadrangularis Linn stem extract by altering Bax-Bcl-2 ratio, release of cytochrome c from mitochondria and PARP cleavage.
Sleep Apnea, Obstructive
The relationship between obstructive sleep apnea and intra-epidermal nerve fiber density, PARP activation and foot ulceration in patients with type 2 diabetes.
Small Cell Lung Carcinoma
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer.
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.
Starvation
Effects of cortisol or starvation on the activities of four enzymes in small intestine and liver of the rat during development.
Stomach Neoplasms
ADPRT Val762Ala and XRCC1 Arg194Trp Polymorphisms and Risk of Gastric Cancer in Sichuan of China.
Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer.
Cochinchina momordica seed extract induces apoptosis and cell cycle arrest in human gastric cancer cells via PARP and p53 signal pathways.
Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency.
Lentivirus-mediated inhibition of USP39 suppresses the growth of gastric cancer cells via PARP activation.
PARP inhibitors target ATM+p53-defective gastric cancer.
Polymorphisms of XRCC1 and ADPRT genes and risk of noncardia gastric cancer in a Chinese population: a case-control study.
SOX2 inhibits cell proliferation and metastasis, promotes apoptotic by downregulating CCND1 and PARP in gastric cancer.
[Correlation of Genetic Polymorphisms in DNA Repair Genes ADPRT and XRCC1 to Risk of Gastric Cancer.]
Stroke
Anti-inflammatory mechanism of taurine against ischemic stroke is related to down-regulation of PARP and NF-?B.
Effect of 3-aminobenzamide, PARP inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model.
Nicotinamide offers multiple protective mechanisms in stroke as a precursor for NAD+, as a PARP inhibitor and by partial restoration of mitochondrial function.
Sex differences in the effects of PARP inhibition on microglial phenotypes following neonatal stroke.
Subarachnoid Hemorrhage
PARP inhibition attenuates early brain injury through NF-?B/MMP-9 pathway in a rat model of subarachnoid hemorrhage.
Thyroid Carcinoma, Anaplastic
PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma.
Thyroid Neoplasms
Association between polymorphisms in DNA base excision repair genes XRCC1, APE1, and ADPRT and differentiated thyroid carcinoma.
The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines.
Triple Negative Breast Neoplasms
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Corrigendum: PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer.
Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
Erratum to "Doubling Down on the PI3K-AKTmTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness" [Neoplasia 16 (2014) 43-72].
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.
Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?
Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer.
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
PARP inhibitor and platinum agent in triple negative breast cancer: utilizing innovative trial design to bring together something "new" and something "old".
PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.
PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.
Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer.
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition.
Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer.
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
Translating the role of PARP inhibitors in triple-negative breast cancer.
Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
Tuberculosis
Mycobacterium tuberculosis Is a Natural Ornithine Aminotransferase (rocD) Mutant and Depends on Rv2323c for Growth on Arginine.
Urinary Bladder Neoplasms
Genetic Variants of XRCC1, APE1, and ADPRT Genes and Risk of Bladder Cancer.
New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment.
Urinary Retention
PARP inhibition prevents oxidative injury of bladder induced by acute urinary retention and subsequent emptying.
Uterine Cervical Neoplasms
Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.
Vitamin B 6 Deficiency
Effect of pyridoxine deficiency on ornithine aminotransferase in rat kidney and liver.